Top Stories

Moderna and SpaceX highlighted by a fast-growing U.S. fund traded in London


Baillie Gifford U.S. Growth Trust devoted much of its half-yearly report to talking up the prospects of biotech Moderna and rocket launcher SpaceX, two of its investments that helped lift its net asset value during the time frame.

The fund
a component of the FTSE 250
reported that its six months to Nov. 30 net asset value surged 54%, taking its total assets to £810.3 million excluding loans it has made.

The fund said 2021 was looking like “the light at the end of the tunnel” as it highlighted its investment in Moderna, which it has held since the 2018 initial public offering….


World’s ‘moral failure’ WHO says

Previous article

Why ultra-low cost carrier Spirit Airlines is falling behind

Next article

You may also like

Leave a Reply

Notify of

More in Top Stories